Generic Name: axitinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Inlyta is a kinase inhibitor approved for previously treated advanced kidney cancer (renal cell carcinoma).
Inlyta is a kinase inhibitor that blocks the action of enzymes, including VEGFR, which plays a role in cancer cell growth and development of blood vessels that feed tumors.
A Phase III trial showed that Inlyta improved progression-free survival compared with Nexavar (sorafenib). Inlyta was first approved in 2012.
Dosing Info: Inlyta is given as a twice-daily tablet.
Common side effects include diarrhea, high blood pressure, fatigue, weakness, loss of appetite, nausea, vomiting, dysphonia (larynx spasms) and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include severe hypertension, severe bleeding, blood clots, heart failure, gastrointestinal perforation, hypothyroidism and liver enzyme elevation. Inlyta may cause fetal harm if used during pregnancy.
For More Info: https://www.inlyta.com/
Patient Assistance Program Info: https://www.inlyta.com/financial-assistance
Last Reviewed: March 24, 2019